Mitochondria-specific RNA-modifying Enzymes Responsible for the Biosynthesis of the Wobble Base in Mitochondrial tRNAs by Umeda, Noriko et al.
広島大学学術情報リポジトリ
Hiroshima University Institutional Repository
Title Mitochondria-specific RNA-modifying Enzymes Responsible forthe Biosynthesis of the Wobble Base in Mitochondrial tRNAs
Auther(s) Umeda, Noriko; Suzuki, Takeo; Yukawa, Masashi; Ohya,Yoshikazu; Shindo, Heisaburo; Watanabe, Kimitsuna; Suzuki,
Tsutomu
Citation Journal of Biological Chemistry , 280 (2) : 1613 - 1624
Issue Date 2005-01-14
DOI 10.1074/jbc.M409306200
Self DOI
URL http://ir.lib.hiroshima-u.ac.jp/00048781
Right This research was originally published in the Journalof Biological Chemistry. Noriko Umeda, Takeo Suzuki,
Masashi Yukawa, Yoshikazu Ohya, Heisaburo Shindo, Kimitsuna
Watanabe, and Tsutomu Suzuki. Mitochondria-specific RNA-
modifying Enzymes Responsible for the Biosynthesis of
the Wobble Base in Mitochondrial tRNAs. J Biol Chem.
2005; 280:1613-1624. © 2005 by The American Society for
Biochemistry and Molecular Biology, Inc.
Relation
Mitochondria-specific RNA-modifying Enzymes Responsible for the
Biosynthesis of the Wobble Base in Mitochondrial tRNAs
IMPLICATIONS FOR THE MOLECULAR PATHOGENESIS OF HUMAN MITOCHONDRIAL DISEASES*
Received for publication, August 13, 2004, and in revised form, October 26, 2004
Published, JBC Papers in Press, October 26, 2004, DOI 10.1074/jbc.M409306200
Noriko Umeda‡§, Takeo Suzuki‡, Masashi Yukawa¶, Yoshikazu Ohya¶, Heisaburo Shindo§,
Kimitsuna Watanabe¶, and Tsutomu Suzuki‡¶**
From the ‡Department of Chemistry and Biotechnology, Graduate School of Engineering, the ¶Department of
Integrated Biosciences, Graduate School of Frontier Sciences, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku,
Tokyo 113-8656 and the §School of Life Science, Tokyo University of Pharmacy and Life Science, 1432-1
Horinouchi, Hachiouji, Tokyo 192-0392, Japan
Humanmitochondrial (mt) tRNALys has a taurine-con-
taining modified uridine, 5-taurinomethyl-2-thiouridine
(m5s2U), at its anticodon wobble position. We previ-
ously found that the mt tRNALys, carrying the A8344G
mutation from cells of patients with myoclonus epilepsy
associated with ragged-red fibers (MERRF), lacks the
m5s2U modification. Here we describe the identifica-
tion and characterization of a tRNA-modifying enzyme
MTU1 (mitochondrial tRNA-specific 2-thiouridylase
1) that is responsible for the 2-thiolation of the wobble
position in human and yeast mt tRNAs. Disruption of the
yeast MTU1 gene eliminated the 2-thio modification of
mt tRNAs and impaired mitochondrial protein synthe-
sis, which led to reduced respiratory activity. Further-
more, when MTO1 or MSS1, which are responsible for
the C5 substituent of the modified uridine, was dis-
rupted along withMTU1, a much more severe reduction
in mitochondrial activity was observed. Thus, the C5
and 2-thio modifications act synergistically in promot-
ing efficient cognate codon decoding. Partial inactiva-
tion of MTU1 in HeLa cells by small interference RNA
also reduced their oxygen consumption and resulted in
mitochondria with defective membrane potentials,
which are similar phenotypic features observed in
MERRF.
The precise codon-anticodon pairing that occurs during
translation requires a post-transcriptional modification at the
anticodon first position (the wobble position) of the tRNA (1–4).
In mammalian mitochondrial (mt)1 tRNAs, we recently dis-
covered novel taurine-bearing modified uridines at the wob-
ble position, namely, 5-taurinomethyluridine (m5U) in mt
tRNALeu(UUR) and 5-taurinomethyl-2-thiouridine (m5s2U) in
mt tRNALys (5). We then showed that these wobble modifica-
tions are generated by the direct incorporation of taurine sup-
plied by the medium. This is the first time it has been shown
that taurine is a component of biological macromolecules.
We have also shown that the taurine-bearing modifications
do not occur in mutant mt tRNAs that contain pathogenic point
mutations that are associated with mitochondrial encephalo-
myopathies (6, 7). Point mutations in mt tRNA genes are
known to be responsible for a wide spectrum of human diseases
that are caused by mitochondrial dysfunction. We found that
the mt tRNALeu(UUR) molecules obtained from pathogenic cells
of MELAS (mitochondrial myopathy, encephalopathy, lactic
acidosis, and stroke-like episodes) patients (8), who have either
the A3243G or the T3271C mutation, lack the m5U modifica-
tion (6). To examine decoding disorder of the mutant tRNA due
to the wobble modification deficiency independent of the path-
ogenic point mutation itself, we used a molecular surgery to
construct a mt tRNALeu(UUR) lacking the taurine modification
but without the pathogenic mutation. This “operated” mt
tRNALeu(UUR) without the taurine modification showed se-
verely reduced UUG translation but no decrease in UUA trans-
lation. We thus concluded that the UUG codon-specific trans-
lational defect of the mutant mt tRNALeu(UUR) is the primary
cause of MELAS at the molecular level (9). This result could
explain the complex I deficiency observed clinically in MELAS.
In addition, mt tRNALys molecules bearing the A8344G muta-
tion that were obtained from cybrid cells of patients with
MERRF (myoclonus epilepsy associated with ragged-red fibers)
(10) were found to lack the m5s2U modification (7). Thus, the
MELAS and MERRF mitochondrial diseases are both associ-
ated with a lack of taurine modification of their mutant tRNAs.
We examined the translational ability of the mutant mt
tRNALys molecules obtained from cybrid cells of MERRF pa-
tients who carry the A8344G mutation. This analysis revealed
that the tRNALys that lacks the m5s2U modification was in-
capable of translating both of its cognate codons, AAA and
AAG, due to complete loss of codon-anticodon pairing on the
ribosome (11). This suggests that the taurine wobble modifica-
tion-deficiency results in a translational defect and that this is
likely to contribute significantly to the mitochondrial dysfunc-
* This work was supported by grants-in-aid for scientific research on
priority areas from the Ministry of Education, Science, Sports, and
Culture of Japan, and by a grant from the New Energy and Industrial
Technology Development Organization (to T. S.). The costs of publica-
tion of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked “advertisement”
in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted
to the GenBankTM/EBI Data Bank with accession number(s) AB178028
 Present address: Biological Information Research Center, National
Institute of Advanced Industrial Science and Technology, 2-41-6 Aomi,
Koto-ku, Tokyo 135-0064, Japan.
** To whom correspondence should be addressed: Tel.: 81-3-5841-
8752; Fax: 81-3-3816-0106; E-mail: ts@chembio.t.u-tokyo.ac.jp.
1 The abbreviations used are: mt, mitochondrial; MELAS, mitochondrial
myopathy, encephalopathy, lactic acidosis, and stroke-like episodes;
MERRF, myoclonus epilepsy associated with ragged-red fibers; ORF, open
reading frame; RT, reverse transcription; LC/MS, liquid chromatography/
mass spectrometry; APM, ((N-acryloylamino)phenyl)mercuric chloride;
EGFP, enhanced green fluorescent protein; siRNA, small interference RNA;
GAPDH, glyceraldehyde-3-phosphate dehydrogenase; cmnm5U, 5-car-
boxymethylaminomethyluridine; cmnm5s2U, 5-carboxymethylamino-
methyl-2-thiouridine; m5s2U, 5-taurinomethyl-2-thiouridine; mnm5s2U,
5-methylaminomethyl-2-thiouridine; s2U, 2-thiouridine.
THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 280, No. 2, Issue of January 14, pp. 1613–1624, 2005
© 2005 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in U.S.A.
This paper is available on line at http://www.jbc.org 1613
 at H
IRO
SH
IM
A
 U
N
IV
ERSITY
 on M
arch 12, 2020
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
tion associated with the pathogenic A8344G mt tRNA muta-
tion. Notably, it has been suggested that it is the lack of the
2-thio modification of the MERRF mutant mt tRNA that is the
main reason for the decoding disorder associated with this
mutation, because it was observed that the 2-thio modification
of mnm5s2U (5-methylaminomethyl-2-thiouridine) in Esche-
richia coli tRNALys is responsible for stabilizing their codon-
anticodon interactions (12). However, it has also been shown
that the C5-taurinomethyl modification also apparently con-
tributes to the efficient codon recognition of the tRNALys (5, 13).
We speculated that the pathogenic point mutation hinders
the biosynthesis of the 2-thio as well as C5-taurinomethyl
modifications of m5s2U. It will be necessary to identify and
characterize the enzyme genes that are responsible for intro-
ducing the 2-thio and C5-taurinomethyl groups onto the wobble
position of tRNALys before we can elucidate the true molecular
reason for the pathogenic nature of the mt mutations associ-
ated with MERRF, as well as with other mitochondrial dis-
eases. This will hopefully lead to the development of therapeu-
tic measures for these diseases. The biosynthesis of the m5s2U
2-thio and C5-taurinomethyl modifications of mt tRNALys prob-
ably involves complicated systems that require many genes,
including several unidentified genes. In the case of the C5
modification of the wobble uridines, mnmE (trmE) and gidA
are known to be required for the initial step in the modification
of E. coli tRNAs, namely, mnm5U (5-methylaminomethyuri-
dine) synthesis (14–16).MSS1 andMTO1 were found to be the
respective homologs of the mnmE and gidA genes in both
human and yeast (17, 18). The protein products of these genes
were shown to localize in the mitochondria as a heterodimer
complex, and their mutants are associated with respiratory
defects (19). These observations suggest that the humanMSS1
and MTO1 genes encode the enzymes that are responsible for
the initial C5-taurinomethyl modification of mt tRNAs, al-
though there is no direct evidence for this as yet. Concerning
the 2-thio modification of the modified wobble uridines, it has
been recently shown by Nakai et al. (20) that the yeast Nfs1p
protein is involved in the 2-thio modification of both mitochon-
drial and cytoplasmic tRNAs. Nfs1p is a eukaryotic homolog of
the bacterial IscS protein that serves to supply activated sulfur
from cysteine to be utilized in iron-sulfur cluster biogenesis
(21–23). IscS (cysteine desulfurase) was also found to be in-
volved in the thio modifications of bacterial tRNAs (24, 25). It
can be assumed that the sulfur of the cysteine is initially taken
up by IscS and is then transferred onto unidentified sulfur
mediators. An enzyme that is directly responsible for the 2-thio
modification of the tRNAs finally then introduces the sulfur
from the mediator onto its target tRNA molecules.
In this study, we report our identification of a mitochondria-
specific tRNA-modifying enzyme that appears to be responsible
for the 2-thio modification of m5s2U in tRNALys. We have
denoted this enzyme as MTU1 (mitochondrial tRNA-specific
2-thiouridylase 1). We also describe our observations that sug-
gest that a deficiency in the 2-thio modification of mt tRNA is
a major molecular cause of the pathogenesis of the MERRF-
associated mutation in the mt tRNALys molecule.
EXPERIMENTAL PROCEDURES
Yeast Strains and Media—Haploid Saccharomyces cerevisiae strains
that lack single genes due to deletion by using the KanMX4 cassette
(26) were purchased from the EUROSCARF collection (available at
www.uni-frankfurt.de/fb15/mikro/euroscarf/). The BY4741 (MATa)
strain was used as the wild type. 0 cells of the BY4741 strain were
constructed as described previously (27). Complete deletion of the mt
DNA was checked by Southern blotting (data not shown). Homologous
recombination in meiosis was employed to obtain haploid cells with
double gene deletions. Thus, the MTU1 strain (EUROSCARF Y03729,
MATa) was mated with the MTO1 or MSS1 strain (the EURO-
SCARF numbers are Y14603 and Y10598, respectively,MAT), and the
diploid cells were selected on SD plates without methionine and lysine.
These heterozygous strains were then sporulated and subjected to tet-
rad analysis. The tetrads displaying 2:2 segregation viability were
selected on YPD (1% yeast extract (Difco), 2% bacto peptone (Difco), and
2% glucose) with G418, and the viable spores lacking the two genes
were obtained as haploid cells with theMATa type. This was checked by
mating tests. The growth properties and mitochondrial activities of
these double deletion strains were compared with those of the single
deletion strains with theMATa type, namely, BY4741 (MATa), MTU1
(EUROSCARF Y03729), MTO1 (EUROSCARF Y04603), and MSS1
(EUROSCARF Y00598). The media used to grow the yeast were the
fermentable medium YPD, the non-fermentable medium YPG (1% yeast
extract, 2% bacto peptone, and 3% glycerol), and the minimal medium
SD (0.67% yeast nitrogen base without amino acids (Difco) and 2%
glucose supplied with the amino acids required). For tetrad analysis,
presporulation medium (0.5% yeast extract, 1% peptone, and 0.17%
yeast nitrogen base without ammonium sulfate and amino acids, 50 mM
potassium phosphate buffer, pH 5.0, 1% potassium acetate, and 0.5%
ammonium sulfate) and sporulation medium (1% potassium acetate
with the appropriate nutrients as required) were used.
Plasmid Construction and Site-directed Mutagenesis—The yeast
MTU1 gene, including its promoter region (1 kbp of 5-untranslated
region), was obtained from the S. cerevisiae genome by PCR using the
following primers: yMTU1-5XhoI (5-gaccactcgagtggctaattctctggaaggc-
3) and yMTU1-3BamHI (5-gattcggatccttatcatcactatgcatggg-3). The
PCR product was cloned into pYO325LEU2 (derived from pRS315) (28) to
yield pYMTU1. The ORF region of human MTU1 (GenBankTM accession
number AB178028) was obtained by nested RT-PCR from the total RNA
of HeLa cells. The first RT-PCR was performed with the primers
hMTU1-F1 (5-aaggcgcggaagcggcggtagctgc-3) and hMTU1-R1 (5-cccagc-
catgggtcctgctctccag-3), which amplified the MTU1 ORF along with both
untranslated regions. The second PCR was carried out with the primers
hMTU1-F2 (5-ggcaatcgattcaagtcagataacaatgcaggccttgcggcacgtcgtgtg-3)
and hMTU1-R2 (5-aaggttcggatcctcagagcaagggactcaggcct-3), which
yielded cDNA of the human MTU1 ORF attached with sufficient edge
remaining that could be used in PCR ligation that would attach the yeast
promoter region to its 5-end. To do this, the promoter region of the yeast
MTU1 gene was amplified with the primers yMTU1-5XhoI and
yMTU1-PR (5-cacacgacgtgccgcaaggcctgcattgttatctgacttgaatcgattg-3).
The sequence of yMTU1-PR is complementary to the hMTU1-F2 se-
quence. The ORF region of human MTU1 was then ligated to the pro-
moter region of the yeastMTU1 gene by using the primers yMTU1-5XhoI
and hMTU1-R2. The product was then cloned into pYO325LEU2 to yield
pHMTU1. We employed a QuikChange site-directed mutagenesis accord-
ing to the manufacturer’s instruction to introduce the D38Amutation into
the yeast MTU1 protein and the D18A mutation into the human MTU1
protein. The primers yMTU1D38A-F (5-gatagtggcaatgtcatctggggtagcttc-
ctctgtggcggcagcac-3) and yMTU1D38A-R (5-gtgctgccgccacagaggaagctac-
cccagatgacattgccactatc-3) were used to introduce the yeast MTU1-D38A
mutation. The primers hMTU1D16A-F (5-ctgtccggcggcgtggccagcgccgtgg-
cc-3) and hMTU1 D16A-R (5-ggccacggcgctggccacgccgccggacag-3) were
used for human MTU1-D18A mutation.
RNA Preparation and mt tRNA Isolation—Total RNAs from yeast
cells was extracted with phenol, precipitated with ethanol, and washed
with 70% ethanol as described (29) and then fractionated with DEAE-
Sepharose Fast Flow (2  30 cm) (Amersham Biosciences) with a linear
gradient of NaCl (200–500 mM) and MgCl2 (2–16 mM) in a buffer
containing 20 mM HEPES-KOH (pH 7.5). The fractions enriched with
tRNAs were pooled and precipitated with ethanol. The mt tRNAs was
homogeneously isolated from the fraction by an improved solid-phase
DNA probe method that we have named chaplet column chromatogra-
phy (30). The 3-biotin-labeled synthetic DNA probe for mt tRNALys
employed in this study is as follows: 5-tggtgagaatagctggagttgaaccaa-3.
Eighty micrograms of DNA probe was immobilized on 200 l of avidin-
Sepharose (50% slurry, Amersham Biosciences) and packed in a small
chaplet column. The tRNA fraction dissolved in binding buffer (1.2 M
NaCl, 30 mM HEPES-KOH, pH 7.5, and 15 mM EDTA) was circulated
through the column by a peristaltic pump at a temperature of 65 °C.
After washing out nonspecifically bound tRNAs with wash buffer (0.6 M
NaCl, 15 mM HEPES-KOH, pH 7.5, and 7.5 mM EDTA), each tRNA was
eluted from the column with elution buffer (20 mM NaCl, 0.5 mM
HEPES-KOH, pH 7.5, and 0.25 mM EDTA) at 65 °C. The eluted mt
tRNALys was further purified by electrophoresis through a 12% poly-
acrylamide gel containing 7 M urea.
Mass Spectrometry—An LCQ ion-trap (IT) mass spectrometer (Ther-
moFinnigan) equipped with an electrospray ionization source and an
HP1100 liquid chromatography system (Agilent) was used to analyze
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the total nucleosides and the RNase T1-digested tRNA. Nucleoside
analysis of total RNA was performed as described previously (30, 31).
We identified each ribonucleoside by comparing its retention time in
mass chromatogram, exact m/z values of proton adduct [MH] and
base fragment ion BH2 with the data base for LC/MS analysis of
ribonucleosides as described (53). As for cmnm5U, we confirmed its
retention time and mass spectrum by comparing with chemically syn-
thesized cmnm5U (kindly provided by Dr. Murao). The exact mass of
each RNA fragment produced by RNase T1 digest was determined by
deconvoluting its multiply charged ions in the mass spectrum. Together
with the information on a species of modified nucleosides in the tRNA
and direct RNA sequencing by Donis-Keller’s method (54), we could
confirm the exact sequence of each RNA fragment.
Purified tRNA (0.05 A260/2.5 g) was digested with RNase T1 (2.5
units) in 20 mM NH4OAc (pH 5.3) at 37 °C for 30 min and then analyzed
by mass spectrometry. The oligonucleotides produced by RNase T1
digestion were analyzed as the negative ion form by LC/MS as described
(32). Purified or unpurified tRNAs (0.02 A260unit) were digested by
nuclease P1 for 3 h at 37 °C in 25 l of reaction mixture containing 20
mM HEPES-KOH (pH 7.5) and 0.5 l of 1 mg/ml nuclease P1 and 0.5 l
of 0.05 unit/ml bacterial alkaline phosphatase.
APM Gel Electrophoresis and Northern Blotting to Detect the Thio-
uridine Modification—The presence of the thiouridine modification in
the purified tRNAs was verified by the retardation of electrophoretic
mobility in a polyacrylamide gel that contains 0.05 mg/ml ((N-acrylo-
ylamino)phenyl)mercuric chloride (APM) (30, 33), which is a method
that was originally developed by Igloi (34). Thus, 0.05 A260 unit of total
RNA was separated by polyacrylamide gel electrophoresis and blotted
onto Hybond Nmembranes (Amersham Biosciences). Each tRNA frac-
tion was detected with a 5-32P-labeled oligonucleotide probe whose
sequence was based on a specific sequence in the corresponding tRNA.
The following oligonucleotides were used: 5-tggtgagaatagctggagtt-
gaac-3 for mt tRNALys; 5-tggttgaatcggtttgattcgaac-3 for mt tRNAGln;
5-tggtaaccttaatcggaatcgaac-3 for mt tRNAGlu; and 5-tggctcctcat-
agggggctcgaac-3 for cytosolic tRNALys2
UUU. After hybridization, the mem-
branes were washed, dried, and then placed in contact with the imaging
plate for 1 h to detect the cytosolic tRNAs and for more than 24 h to
detect the mt tRNAs. The radioactivities were detected with a BAS5000
bioimaging analyzer (Fuji Photo Systems).
Pulse-labeling of Mitochondrial Protein Synthesis—The [35S]methi-
onine incorporation into mitochondrial proteins encoded by mt DNA
was basically performed as described previously (35). Thus, yeast cells
incubated with sulfur-lacking medium were harvested and cyclohexi-
mide (final concentration, 150 g/ml) was added to inhibit cytoplasmic
protein synthesis. The cells were then labeled with [35S]methionine (54
mCi/mmol, Amersham Bioscience) at a concentration of 107 cells/ml/80
Ci for 10 min at 30 °C. The total proteins from the cells were separated
by SDS-PAGE, and the gel was dried and exposed to an imaging plate.
The radiolabeled mitochondrial proteins were detected with a BAS5000
bioimaging analyzer (Fuji Photo Systems).
Subcellular Localization of MTU1 Protein—The ORF of human
MTU1was amplified from pHMTU1 by PCR using the primers hMTU1-
5XhoI (5-ggccactcgagatgcaggccttgcggcacg-3) and hMTU13BamHI
(5-ggttcggatcccggagcaagggactcaggc-3) and cloned between the XhoI
and BamHI sites of pEGFP-N1 (Clontech) to yield pHMTU1/EGFP,
which expresses a reporter MTU1 fused to the N terminus of EGFP. The
resultant plasmid was transfected into 2  105 HeLa cells by using a
LipofectAMINE reagent (Invitrogen) according to the procedure recom-
mended by the manufacturer. After 24 h of transfection, the mitochon-
dria were stained by MitoTracker Red (Molecular Probes), and the red
fluorescence of MitoTracker Red and the green fluorescence of EGFP
were simultaneously observed by confocal fluorescence microscopy
(Leica DEMIRBE).
siRNA Transfection—Five siRNAs targetingMTU1were designed by
an RNA interference activity-predicting algorithm that was developed
by our group.2 These siRNAs were synthesized by a method used to
synthesize siRNAs derived from in vitro transcribed short hairpin RNA
(36). The sequences of the sense strand of each siRNA are as follows:
MTU1-1 (5-aguuugcuguguucuacaa-3), MTU1-2 (5-acguaaaggaguau-
uggaa-3), MTU1-3 (5-gaaugaguaugaaaaagga-3), MTU1-4 (5-guuu-
gaaguuagaaaugcg-3), and MTU1-5 (5-gucacuuuauuuccauaga-3). The
siRNA for luciferase (5-cguacgcggaauacuucgaag-3) was used as a neg-
ative control. The cells were cultured in Dulbecco’s modified Eagle’s
medium with F-12 containing 10% fetal bovine serum, 100 units/ml
penicillin, and 100 g/ml streptomycin and 7.5  104 cells/well were
then inoculated in 6-well plates and cultivated for 48 h. The medium
was then changed to 1 ml of Opti-MEM I (Invitrogen) per well. The cells
were transfected with 10 mol of the siRNAs for MTU1 or luciferase
(final concentration, 50 nM) by using 10 l of Oligofectamine (Invitro-
gen). They were then incubated for 4 h. Thereafter, 500 l of Dulbecco’s
modified Eagle’s medium with 30% fetal bovine serum was added. 96 h
after the transfection, the total RNAs were extracted from the cells
using TRI reagent (Sigma) according to the manufacturer’s instruction.
RT-PCR was carried out to measure the knocking down of the MTU1
mRNA levels. Thus, 100 ng of the total RNAs from the cells that had
been transfected withMTU1-siRNA or luciferase-siRNA were subjected
to RT-PCR (Qiagen OneStep RT-PCR kit) as templates using theMTU1
primers MTU1-F3 (5-aggtgacaggggtgtttatg-3) and MTU1-R3 primer
(5-cttgcatagtgacctgtggc-3) and the glyceraldehyde-3-phosphate dehy-
drogenase primers GAPDH-F2 (5-gtcgccagccgagccacat-3) and
GAPDH-R2 (5-tcgttgtcataccaggaaatga-3). The cycle number employed
was 35.
Visualizing Mitochondrial Membrane Potential—72 h after the
transfection of siRNA targeting MTU1, the cells were stained with both
MitoTracker Red (final concentration, 50 nM) and MitoTracker Green
(final concentration, 100 nM). As a control, we used cells that had been
transfected with an siRNA-targeting luciferase. The cells were washed
with phosphate-buffered saline, and 1 ml of medium was added. The
cells were then visualized by confocal fluorescence microscopy (Leica
DEMIRBE).
Oxygen Consumption—The rate of oxygen consumption by yeast cells
(A600  0.4) cultured in 4 ml of YPD was measured for 15 min at 30 °C
or 37 °C by using a Clark type electrode (YSI 5300A Biological Oxygen
Monitor System). The HeLa cells were trypsinized and adjusted to 5 
105 cells/ml. The rate of oxygen consumption was monitored for 45 min
at 37 °C.
RESULTS
Identification of Mitochondrial tRNA-specific 2-Thiouridyl-
ase (MTU1)—It has been reported that the Escherichia coli
iscS and mnmA (trmU and asuE) genes encode enzymes that
are responsible for biosynthesizing the 2-thio group of
mnm5s2U (37, 38). Moreover, recombinant IscS has been shown
to cooperate with MnmA to synthesize the 2-thio modification
of tRNA in vitro (39). MnmA is believed to act in 2-thiouridyl-
ation by recognizing the substrate tRNA. Thus, we speculated
that the mitochondrial mnmA homolog may be a candidate
gene that introduces the 2-thio group of m5s2U in mt tRNALys.
We obtained the mnmA homologs in yeast, Caenorhabditis
elegans, Drosophila, mice, and humans by BLASTP searches of
protein databases. Sequence alignment revealed considerable
conservation between these sequences (Fig. 1). The N-terminal
regions contain a highly conserved SGGXDS sequence that is
predicted to be a P-loop motif, which is a common ATP-binding
motif found in the ATP pyrophosphate (pyrophosphate synthe-
tase) family (40).
YDL033c is the S. cerevisiae yeast homolog of mnmA. It
shows 29 and 24% homology to the sequences of the E. coli
mnmA gene and its human homolog, respectively. It is a non-
essential gene whose deletion strain is available (26). Thus, to
examine the involvement of YDL033c in the 2-thio modification
of the mt tRNAs for Lys, Glu, and Gln and the cytosolic
tRNALys, total RNAs obtained from the YDL033c-deletion
strain were subjected to polyacrylamide gel electrophoresis
containing (N-acryloylamino)phenylmercuric chloride (APM)
combined with Northern blotting (33, 34) (see “Experimental
Procedures”) (Fig. 2). The four tRNAs from the wild type strain
show specific retardation in the APM-containing polyacryl-
amide gel due to the strong affinity of the 2-thio group in these
tRNAs with the mercuric compound in the gel (Fig. 2, A–D, lane
1). We have confirmed that no other thio modifications in these
tRNAs are responsible for their gel-retardation in this experi-
ment (data not shown). In the case of the tRNAs from the
deletion strain, the retarded bands for the three mt tRNAs
were not observed (Fig. 2, A–C, lane 2). However, the cytosolic
tRNALys molecule was still specifically retarded. This suggests2 T. Katoh and T. Suzuki, manuscript submitted.
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that YDL033c is responsible for the 2-thio modification of mt
tRNAs.
To confirm these observations, the mt tRNALys molecules
(Fig. 3A) were isolated from the wild type strain and the
MTU1 deletion strain and subjected to LC/MS analyses.
Nucleoside analysis revealed that the mt tRNA from the
wild type cells contains cmnm5s2U (5-carboxymethylamino-
methyl-2-thiouridine) and its precursor cmnm5U (5-carboxy-
methylaminomethyluridine) as the wobble modification (Fig.
3B, left panel). In the mt tRNALys from the deletion strain,
however, there was a marked increase in the cmnm5U peak,
and the cmnm5s2U peak disappeared (Fig. 3B, right panel).
The purified mt tRNAsLys molecules from the wild type and
mutant strains were also subjected to RNase T1 digestion,
which cleaves off the anticodon-containing fragment (Fig.
3A), and this fragment was then analyzed by LC/MS (Fig.
3C). In the wild-type mt tRNALys, an anticodon-contain-
ing RNA fragment consisting of cmnm5s2U (5-
CUcmnm5s2UUUt6AAGp-3 (3105.9 Da)) was prominently
detected, whereas a fragment containing cmnm5U instead of
cmnm5s2U (5-CUcmnm5UUUt6AAGp-3 (3089.9 Da)) was
detected as a minor product. In contrast, in the tRNA mole-
cules from the deletion strain, the cmnm5U-containing frag-
ment was detected as the major product and no cmnm5s2U-
containing fragments could be seen. Thus, YDL033c encodes
an enzyme that is responsible for synthesizing the 2-thio
group on cmnm5s2U in the three mt tRNAs for Lys, Glu, and
Gln. Thus, we have named this gene MTU1 (mitochondrial
tRNA-specific 2-thiouridylase 1).
Direct Evidence of the Requirement of MTO1 and MSS1 in
the C5 Modification of the Wobble Uridine in mt tRNAs—In the
modification of the E. coli tRNAs, the initial step of mnm5U
synthesis is known to require the mnmE (trmE) gene, because
the disruption ofmnmE resulted in defective mnm5U synthesis
(14, 41). The gidA gene also appears to be involved, as sug-
gested by indirect genetic evidence (15, 16). Although MSS1
and MTO1 were found to be the respective homologs of the
mnmE and gidA genes in both human and yeast (17, 18), it has
FIG. 1. Sequence alignment of mt tRNA-specific 2-thiouridylases. Human MTU1 (AB178028) was aligned with its mouse (AAH61026),
yeast (Scere, CAA98591), C. elegans (Celeg, Q17440), D. melanogaster (Dmela, AAE45578), and E. coli counterparts (P25745). Multiple alignment
of each sequence was performed by using ClustalW (62) and displayed using the Genedoc multiple sequence alignment editor. Homology values
(between the human sequence and the others), as calculated by Genedoc (63), are shown at the end of the alignment. The colored boxes indicate
the degree of sequence similarity. The P loop motif (12–17) is indicated by a dotted red line.
FIG. 2. APM gel electrophoresis combined with Northern blot-
ting of yeast mitochondrial tRNAs. The presence of 2-thio modifi-
cations of the mt tRNAGln (A), mt tRNALys (B), mt tRNAGlu (C), and
cytoplasmic tRNALys (D) molecules in wild type yeast (lanes 1 and 3) or
MTU1 yeast (lanes 2 and 4) were analyzed by APM gel electrophoresis
and Northern blotting. The gels of lanes 1 and 2 contain APM, whereas
the gels of lanes 3 and 4 lack APM. The retarded bands of the 2-thio-
lated tRNAs are marked by a black arrowhead, whereas the non-
retarded bands of the unthiolated tRNAs are marked by a gray
arrowhead.
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never been demonstrated that these mitochondrial proteins are
responsible for biosynthesizing the C5 modification of wobble
uridines in mt tRNAs. To test this notion, yeast mt tRNAsLys
(Fig. 3A) molecules were isolated from MTO1 and MSS1 dele-
tion strains and subjected to LC/MS analyses. First, total nu-
cleoside analysis revealed that the mt tRNAsLys from both
deletion strains contains s2U (2-thiouridine) instead of the
cmnm5s2U found in the wild type tRNALys molecules (data not
shown). RNA fragment analyses by LC/MS then also showed
that the anticodon-containing RNA fragment of the mt
tRNAsLys molecules from the MTO1 and MSS1 strains bear
s2U (5-CUs2UUUt6AAGp-3 (3018.9 Da)) but not cmnm5s2U
(Fig. 3C). These results directly show that MSS1 and MTO1
genes are both involved in the biosynthesis of the 5-carboxy-
methylaminomethyl group of cmnm5s2U of mt tRNALys.
Synergism of MTU1 with MTO1 and MSS1 in Promoting
Efficient Mitochondrial Decoding—To determine the physiolog-
ical effects of deleting yeast MTU1, the respiratory activity of
the MTU1 strain was examined by analyzing its growth on
non-fermentable (YPG) and fermentable (YPD) medium plates
and by determining its oxygen consumption. As a control, 0
cells grew normally on fermentable medium (YPD) but did not
grow on the non-fermentable YPG plate (Fig. 4A). Growth
defects of MTU1 on the YPD plate were not seen, but signif-
icant growth defect could be observed on the YPG plate. This
can be explained by the fact that MTU1 showed strongly
defective oxygen consumption (Fig. 4B). In addition, when we
analyzed the mitochondrial protein synthesis in the wild type
FIG. 3.Mass spectrometric analysis of the tRNAs from the wild type and MTU1 yeast strains. A, the secondary structure of yeast mt
tRNALys bearing the following post-transcriptional modifications: dihydrouridine (D), pseudouridine (), ribothymidine (T),N6-threonylcarbamoyl-
adenosine (t6A), 5-carboxymethylaminomethyl-2-thiouridine (cmnm5s2U), 5-carboxymethylaminomethyluridine (cmnm5U), and 2-thiouridine
(s2U). The anticodon-containing fragment produced by digesting the tRNA with RNase T1 is colored gray. The cleavage positions are shown by
arrowheads. B, LC/MS analysis of the total nucleosides in the mt tRNALys molecules obtained from the wild type (left panel) and MTU1 (right
panel) strains. Mass chromatograms of cmnm5U (m/z 332 at retention time 13.4, dotted line) and cmnm5s2U (m/z 348 at RT 21.6, solid line) are
shown by the proton adduct form of each nucleoside. Side peaks in RT 15.9 and RT 20.3 (asterisks) are assigned as artifacts with unknown chemical
structures. C, LC/MS fragment analysis of RNase T1-digested mt tRNA
Lys molecules obtained from the wild type, MTU1, MTO1, and MSS1
strains. The mass chromatogram of doubly charged ions in the anticodon-containing fragment bearing cmnm5s2U (m/z 1551) is shown in each of
the upper panels. Mass chromatograms of the same fragments bearing cmnm5U (m/z 1543) are shown in the lower left panels for wild type and
MTU1, whereas the mass chromatograms of the same fragments carrying s2U (m/z 1508) are shown in the lower right panels for MTO1 and
MSS1.
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and MTU1 strains by [35S]Met pulse-labeling experiments,
we found it was severely reduced in the MTU1 strain (Fig.
4C). These results suggest that the 2-thio modification of mt
tRNAs is essential for mitochondrial protein synthesis, which
directly reflects the respiratory activity of mitochondria.
Because MSS1 and MTO1 appear to be responsible for the
biosynthesis of the C5 modification in cmnm5s2U, we assessed
whether the 2-thio group and the C5 modification act synergis-
tically in the decoding activity of mt tRNAs. The MSS1 and
MTO1 strains show a growth phenotype that is similar to that
of the wild-type cell on both YPD and YPG plates (Fig. 4A), as
has been previously reported for cells with paromomycin-sen-
sitive genetic backgrounds (19, 42). However, both MSS1 and
MTO1 did show decreased rates of oxygen consumption (Fig.
4B), which indicates that defective C5 modification causes mi-
tochondrial dysfunction to some extent, although the effect is
weaker than that of MTU1. We then constructed two double
knock-out strains, namely, MTU1/MSS1 and MTU1/
MTO1, which should contain mt tRNAs with unmodified wob-
ble uridines, because C5 and 2-thio modifications occur inde-
FIG. 4.Growth properties andmitochondrial activity of strains lacking the enzymes that modify the wobble position of mt tRNAs.
A, growth of the wild type, three single deletion mutant (MTU1, MTO1, and MSS1) and two double deletion mutant (MTU1/MSS1 and
MTU1/MTO1) strains. Each strain was serially diluted starting with 105 cells and then spotted onto fermentable YPD and non-fermentable YPG
plates and incubated at 30 °C for 72 h. B, oxygen consumption of each mutant strain. The rate of oxygen consumption is shown along with the S.D.
values obtained from three independent experiments. C, mitochondrial protein synthesis in the wild type (lane 1) and MTU1 (lane 2) strains was
determined by in vivo pulse-labeling of mt DNA products with [35S]methionine. The mt DNA products are identified on the left.
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pendently. Both strains showed a severe growth defect on even
the YPD plate, and no growth was observed on the YPG plate
(Fig. 4A). Moreover, almost no respiratory activity could be
seen in either strain (Fig. 4B). The severe phenotypes of these
double knock-out strains demonstrate that both the 2-thio and
C5 modifications are required for efficient decoding in mito-
chondrial translation.
Identification and Characterization of the Human MTU1
Gene—The human homolog of MTU1 was introduced into the
yeast MTU1 strain to see whether it can complement yeast
MTU1. The MTU1 strain bearing the human MTU1 gene
(MTU1pHMTU1) was now able to grow on YPG plates (Fig.
5A), and its rate of oxygen consumption was increased slightly
relative to the MTU1 strain (Fig. 5B). The 2-thio modification
of the mt tRNALys in this strain was then examined by APM gel
electrophoresis. This revealed that the introduction of human
MTU1 resulted in a slight but apparent recovery of the 2-thio
modification in the MTU1 strain (Fig. 5C). The relatively
weak complementation observed may be the result of the ex-
perimental system employed here, as we found that placing the
yeast MTU1 gene back into the MTU1 strain by transfecting
the cells with pYMTU1 also did not completely restore the
2-thio modification or the oxygen consumption in the MTU1
strain (Fig. 5C). Thus, it seems that this experimental design
does not lead to complete complementation. Nevertheless,
these experiments still clearly show that the human MTU1
gene works as a 2-thiouridylase in yeast cells.
It has been reported that certain genes responsible for tRNA
modification work not only as tRNA-modifying enzymes but
also as molecular chaperons for tRNAs, because the phenotype
resulting from their gene deletion could be restored by intro-
ducing the enzyme genes that have been inactivated by mutat-
ing the active center of the enzymes (43). To determine whether
the mitochondrial activity associated with MTU1 depends on
its 2-thio modification of the mt tRNAs or another function, we
constructed inactive yeast and human MTU1 mutants by, re-
spectively, introducing the D38A and D16A point mutations
into their P-loops. These mutant genes were then subjected to
the complementation test, but neither promoted YPG plate
growth or oxygen consumption of the MTU1 strain (Fig. 5, A
and B). This indicates that the highly conserved Asp residue in
the P-loop works as an essential residue for both yeast and
human MTU1 and that the enzymatic function of MTU1 is
required for its role in mitochondrial activity.
The subcellular localization of human MTU1 was then ex-
amined by transiently expressing EGFP-fused MTU1 (MTU1-
EGFP) in HeLa cells. Judging from the N-terminal sequences
of human and yeast MTU1, the probability that they localize in
the mitochondria is 0.53% and 0.87%, respectively, according to
PSORT II Prediction analysis (44) (available at psort.nibb.
ac.jp/). As shown in Fig. 5D, MTU1-EGFP indeed localizes
mainly in the mitochondria. Recently, it has been reported
that mouse 5-methylaminomethyl-2-thiouridylate-methyl-
transferase (TRMU) homolog localizes in mitochondria, although
there is no direct evidence of this gene to be responsible for mt
tRNA modification (45). This is consistent with the observation
that MTU1 is a mitochondrial tRNA-specific 2-thiouridylase.
Knocking Down Human MTU1 Results in Mitochondrial
Dysfunction—We have shown that humanMTU1 complements
yeast MTU1 and localizes in mitochondria. To obtain direct
evidence that human MTU1 is responsible for the 2-thio mod-
ification of m5s2U in mt tRNAs, five siRNAs (MTU1-1 through
-5, see “Experimental Procedures”) that target human MTU1
were designed by an algorithm that predicts efficacious siRNA
sequences.2 HeLa cells were transfected with each siRNA or
with siRNA targeting luciferase as a control and harvested 72 h
later. The total RNAs were then subjected to semi-quantitative
reverse transcription (RT)-PCR to estimate the knockdown ac-
tivity of each siRNA. Each of the five MTU1 siRNAs caused a
potent reduction in the MTU1 mRNA levels but had no effect
on the glyceraldehyde-3-phosphate dehydrogenase mRNA lev-
els, which served as a control. We chose MTU1-1 siRNA for
further experiment. Judging from the band intensity of the
RT-PCR products, MTU1 mRNA levels clearly decreased by
MTU1-1 siRNA (Fig. 6A). APM gel-Northern analysis was then
carried out to measure the degree of 2-thio modification of mt
tRNALys in the MTU1 siRNA-transfected cells. A large part of
the 2-thiolated tRNALys molecules from control luciferase
siRNA-transfected cells that were retarded in the APM gel
disappeared when MTU1-targeting siRNAs were introduced
(Fig. 6B). The rate of oxygen consumption of theMTU1 siRNA-
transfected cells was also clearly decreased as compared with
the wild-type cells (Fig. 6C), although this is shown as raw
data, because it is difficult to obtain large number of cells that
are transfected by siRNA. We also examined the mitochondrial
membrane potential of the knockdown cells by staining HeLa
cells transfected byMTU1- or luciferase-targeting siRNAs with
both MitoTracker Red and Green, which are fluorescent indi-
cators for staining mitochondria (Fig. 6D). MitoTracker Red is
an indicator of mitochondrial membrane potential (). The
mitochondria of the control luciferase siRNA-transfected cells
showed good staining with both dyes, and when the two images
were superimposed they revealed a well developed meshwork.
In contrast, the MTU1-knockdown cells had granular-shaped
mitochondria that stained poorly with MitoTracker Red. Thus,
knocking down human MTU1 results in mitochondria with a
defective membrane potential, which is consistent with a phe-
notypic feature of cells from MERRF patients who carry the
A8344G mutation (46, 47).
DISCUSSION
In this study, we describe our identification of MTU1 as a
mitochondrial-specific 2-thiouridylase that is responsible for
the wobble modification of yeast and human mt tRNAs. The
disruption of yeastMTU1 results in a 2-thio modification defect
in the three mt tRNAs (for Lys, Glu, and Gln) that were
examined. Pulse-labeling experiments with the MTU1 strain
indicated that the 2-thio modification of the mt tRNAs is re-
quired for efficient mitochondrial protein synthesis. The hu-
man homolog ofMTU1 complemented the MTU1 strain as its
introduction caused the 2-thio modification of mt tRNAs and
the oxygen consumption of the strain to recover slightly. More-
over, siRNA-induced knocking down of human MTU1 in HeLa
cells resulted in a 2-thio modification defect in their mt tRNAs.
This is the first time a reverse genetic approach utilizing
siRNA to study a mammalian RNA modification enzyme has
been reported. This specific repression of the human MTU1
gene resulted in reduced oxygen consumption and defective
mitochondrial membrane potentials. This nicely explains our
previous observation that the wobble modification deficiency of
mt tRNALys bearing the 8344 mutation results in poor decoding
of cognate codons (11). However, it should be noted that the
effects of knocking downMTU1may not completely correspond
to the consequences of the 8344 mt tRNALys mutation, because
MTU1 suppression may cause three mt tRNAs for Lys, Glu,
and Gln to be inadequately modified. Consequently, it is likely
that the knockdown ofMTU1 causes the wobble base of the mt
tRNAs for Lys, Glu, and Gln to lack the 2-thio modification and
therefore to only carry the m5U modification. The MERRF-
associated 8344 mutation, on the other hand, results in the
complete absence of any modifications of mt tRNALys only (i.e.
both the C5 and 2-thio modifications are absent). Nevertheless,
our observations indicate that the 2-thio modification defi-
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FIG. 5. Suppression of the respiratory defect of MTU1 by introducing the human or yeast MTU1 genes and mitochondrial
localization of the MTU1 protein. A, growth of the wild type, MTU1, and the MTU1 strain bearing a plasmid encoding the yeast MTU1
(pYMTU1) or human MTU1 (pHMTU1) gene. Also examined were MTU1 strains bearing pYMTU1 or pHMTU1 containing an inactivating
mutation (pYMTU1-D38A and pHMTU1-D16A, respectively). Starting with 105 cells, serial dilutions were spotted onto YPD, and YPG plates and
incubated at 30 °C for 72 h. B, rate of oxygen consumption for each strain. The rate of oxygen consumption is shown along with the S.D. values
obtained from three independent experiments. C, APM-Northern analysis of the 2-thiolation in the mt tRNALys molecules from the wild type (lanes
1 and 5), MTU1 (lanes 2 and 6), MTU1 with pYMTU1 (lanes 3 and 7), and MTU1 with pHMTU1 (lanes 4 and 8) strains. The polyacrylamide
gels of lanes 1–4 contain APM, while the gels of lanes 5–8 lack APM. The retarded bands of the 2-thiolated tRNAs are marked by a black
arrowhead. The non-retarded bands of the non-thiolated tRNA are marked by a gray arrowhead.D, mitochondrial localization of the MTU1 protein.
HeLa cells were transiently transfected with pHMTU1/EGFP, which expresses human MTU1 fused with EGFP. The intracellular localization of
the MTU1-EGFP fusion protein was then visualized by the green fluorescence of EGFP by using a confocal fluorescence microscope (left panel). The
mitochondria were stained by MitoTracker Red (Molecular Probes), and its red fluorescence was simultaneously observed (middle panel). Both
panels were merged (right panel) to show the complete overlap of the two fluorescence patterns.
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ciency of mt tRNA induces strong mitochondrial dysfunction
and that this may at least partly explain the mitochondrial
disorders seen in MERRF patients.
It has been reported that tRNA-modifying enzymes have
other function. An E. coli deletion strain of truB encoding
pseudouridylase for position 55 shows growth defect in co-
culturing with wild type strain. However, the phenotype of this
strain is recovered by introducing a plasmid containing truB
mutant whose product has no catalytic activity (43). In addi-
tion, E. coli trmA encoding m5U54-methyltransferase is an
essential gene, but its catalytic activity for methylation is not
required for cell viability (48). These facts suggest that some
RNA-modifying enzymes are multifunctional proteins. To test
this possibility for yeast MTU1, point mutations D16A and
D38A in the P-loop were respectively introduced into human
and yeast MTU1 proteins. Because these mutants could not
FIG. 6. siRNA-induced knockdown of human MTU1 results in mitochondrial dysfunction. A, the MTU1 mRNA levels of HeLa cells
transfected with siRNAs that target MTU1 (MTU1-1) (lane 2) or luciferase (lane 1) were quantified by RT-PCR (35 cycles). Glyceraldehyde-3-
phosphate dehydrogenase mRNA was quantified as a control. B, APM-Northern analysis of the 2-thiolation of mitochondrial (lanes 1 and 2) or
cytosolic (lanes 3 and 4) tRNAsLys molecules from HeLa cells transfected with siRNAs that target MTU1 (lanes 1 and 3) or luciferase (lanes 2 and
4). The retarded bands of the 2-thiolated tRNAs are marked by a black arrowhead. The non-retarded bands of non-thiolated tRNAs are marked
by a gray arrowhead. C, the rates of oxygen consumption of HeLa cells transfected with siRNAs targeting MTU1 (dotted line) or luciferase (solid
line) were measured by a Clark type electrode. D, visualizing the mitochondrial membrane potential ofMTU1-knocked down HeLa cells. The cells
transfected with siRNAs targeting MTU1 or luciferase are shown in the upper and lower panels, respectively. The mitochondria were visualized
by staining the cells with MitoTracker Green (left panels), and its membrane potentials were simultaneously indicated by staining with
MitoTracker Red (middle panels). Both panels were merged (right panels) to show the different intensities of the two fluorescence patterns.
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complement the MTU1 strain and restore the 2-thio modifi-
cation, the conserved Asp residue in the P-loop is essential for
enzymatic function of MTU1, which seems to be required for
restoration of mitochondrial activity. However, introduction of
a plasmid containing wild type MTU1 did not completely re-
store the 2-thio modification and oxygen consumption of
MTU1 strain, indicating that there is an unknown cis element
for MTU1 expression to be investigated.
MTU1 bears the highly conserved P-loop motif (SGGXDS) in
its N-terminal domain. This motif occurs widely in the pyro-
phosphate synthetase family (Fig. 1) (40). The P-loop is known
to participate in the binding and hydrolysis of the – phos-
phate bond of ATP. Other tRNA-modifying enzymes with the
P-loop motif also exist. One is TilS, an essential tRNA-modify-
ing enzyme that was recently identified by our group to be
responsible for synthesizing lysidine at position 34 of the bac-
terial tRNAIle molecules that are specific for the AUA codon
(31). Also bearing the P-loop motif is ThiI, a thiouridine syn-
thetase that is responsible for the synthesis of 4-thiouridine at
position 8 (s4U8) of bacterial tRNAs (49, 50). Both enzymes
require ATP as the energy source for the reaction, as does
E. coli mnmA, the homolog of MTU1 (39). More recently, TtcA
was identified as a P-loop-containing modification enzyme for
2-thiocytidine at position 32 (s2C32) (51). Thus, the P-loop
motif is commonly found in enzymes responsible for RNA mod-
ifications that target the carbonyl carbon of bases in tRNAs,
which suggests a similar reaction mechanism is involved in
these modifications. According to the reaction mechanism em-
ployed by GMP synthetase, which belongs to the pyrophos-
phate synthetase family (52), it is thus likely that the first step
of 2-thiouridine synthesis is the activation of the C-2 carbonyl
group of the wobble uridine by the addition of AMP to form an
adenylate intermediate. Nucleophilic attack on the adenylate
by an activated sulfur carried on an unidentified protein prob-
ably completes the reaction. The details of the mechanism of
2-thiouridine formation will be clarified in the near future.
It has been shown previously that a mutation in MTO1
caused yeast cells to exhibit a respiratory defect only when
coupled with a paromomycin-resistant mutation in mitochon-
drial 15 S rRNA (19). This phenotype was similar to that
induced by a mutation inMSS1 (42). Indeed, Mto1p and Mss1p
were shown to form a heterodimer complex (19). It has not been
reported for E. coli that the products of the gidA gene (the
bacterial MTO1 homolog) and the mnmE (MSS1 homolog) di-
rectly interact. However, genetic evidence has suggested that
gidA is responsible for C5 modification along with mnmE (14–
16). Nevertheless, direct evidence for this has not been re-
ported. In our study reported here, we show by analyzing the
tRNA molecules from the MTO1 yeast strains that MTO1
(gidA) are indeed responsible for the initial step of C5 modifi-
cation. Disruption of MTO1 or MSS1 resulted in a normal
growth phenotype, even upon culture on YPG plates, which is
consistent with previous reports (19, 42). However, both the
MTO1 and MSS1 strains showed reduced oxygen consump-
tion, which suggests that a decoding disorder arises from a
deficiency in C5 modification of mt tRNAs. Notably, when
MTO1 or MSS1 were disrupted along with MTU1, a severe
reduction in respiratory activity resulted. This indicates that
the C5 and 2-thio modifications of the wobble uridine act syn-
ergistically in promoting cognate codon decoding efficiency.
Because the human homologs of MSS1 and MTO1 have been
shown to be localized in the mitochondria (17, 18), it appears
that these proteins are responsible for the initial steps taken to
synthesize the m5U or m5s2U modifications of mt tRNAs. It is
also likely that there are some unidentified genes other than
MSS1 and MTO1 that participate in these modifications, in-
cluding a putative taurine-transferase for the biosynthesis of
m5U (5). To understand how the C5 modification deficiency
can contribute to the molecular pathogenesis of MELAS, it will
be necessary to identify the enzyme genes that are responsible
FIG. 7. Biosynthetic pathway that introduces the m5s2U (cmnm5s2U) modification of mitochondrial tRNAs. MSS1 and MTO1 are
involved in the initial step of m5s2U (cmnm5s2U) synthesis on mt tRNAs. Mitochondrial taurine or glycine is subsequently incorporated into mt
tRNAs by unidentified transferases to build m5s2U or cmnm5s2U, respectively. Nfs1 is responsible for the initial step in the 2-thiolation of m5s2U
(cmnm5s2U) in mt tRNAs and mcm5s2U in cytoplasmic tRNAs (20). The sulfur from cysteine is transferred to unknown sulfur mediators by Nfs1p.
MTU1 then acts as a mitochondria-specific 2-thiouridylase for m5s2U (cmnm5s2U) by using the activated sulfur from the mediators.
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for the biosynthesis of m5U and to be able to reconstitute this
whole biosynthesis pathway in vitro.
Fig. 7 shows a summary of the m5s2U biosynthetic pathway.
Our analyses of the tRNALys modifications in the MTO1,
MSS1, and MTU1 yeast (Fig. 3C) indicate that both the C5
and 2-thio modifications appear to proceed independently. Con-
cerning the 2-thio modification, Nfs1, an eukaryotic homolog of
bacterial iscS, has been found to be a master enzyme gene
involved in the 2-thio modification of both mitochondrial and
cytoplasmic tRNAs (20). Nfs1p works as a supplier of activated
sulfur from cysteine to be utilized in iron-sulfur cluster biogen-
esis, and it is also known to be involved in thio modifications of
tRNAs. Moreover, it has been reported that recombinant IscS
and MnmA (the MTU1 homolog) cooperate to synthesize 2-thio
modifications in vitro by using ATP and cysteine as substrates
(39). However, we have found that additional genes are indis-
pensable for the biosynthesis of 2-thio modifications in E. coli
tRNAs.3 Thus, there must be sulfur mediators that act between
Nfs1p and MTU1. MTU1 may directly recognize mt tRNAs and
synthesize the 2-thio group by using ATP and the sulfur served
by the mediator. With regard to the C5 modification, we have
shown thatMTO1 andMSS1 are directly involved in the initial
step of its biosynthesis. It is likely that subsequent steps that
involve as yet unknown genes finally lead to the synthesis of
m5s2U through the incorporation of taurine supplied from
plasma (5).
We have shown that MTU1 is not involved in synthesizing
2-thio modification of mcm5s2U in cytoplasmic tRNAs, show-
ing the presence of an unknown enzyme in cytoplasm. It has
been reported that yeast Trm9 gene encodes methyltrans-
ferase which is responsible for C5 modification of mcm5U and
mcm5s2U (53). Although disruption of Trm9 gene resulted in
complete loss of mcm5s2U in tRNAGlu, it is not clear whether
it is an unmodified uridine or s2U in this report. Recently, our
group has demonstrated that tRNAGlu from the Trm9 dele-
tion strain has an unmodified wobble uridine, suggesting
that 2-thio modification occurs in coupling with C5 modifica-
tion in yeast cytoplasm.4 It is a distinct biosynthesis with
bacterial and mitochondrial 5-methyl-2-thiouridine type
modifications (xm5s2U).
In bacterial and mitochondrial tRNAs for Lys, Gln, and Glu,
the U at the wobble position is modified to xm5s2U such as
mnm5s2U, cmnm5s2U, mcm5s2U, and m5s2U (1, 3–5, 54, 55).
Because these tRNAs are responsible for decoding two codon
sets that end in purine (R) (i.e.NNR), the xm5s2Umodifications
participate in preventing the misreading of the pyrimidine
(Y)-ending near cognate codons (NNY) (56). xm5s2U is largely
fixed in the C3-end form (56, 57). Due to this conformational
rigidity, the xm5s2U modification prefers to base pair with A
and prevents misreading of NNY codons (56, 58, 59). In addi-
tion, it was reported that 2-thio modification of mnm5s2U in
E. coli tRNALys confers efficient ribosome binding (12, 55, 60).
Furthermore, the C5-taurinomethyl group of m5U was shown
to be required for the efficient decoding of the UUG codon by
stabilizing the U:G wobble-base pairing on the ribosomal A site
(9, 61).
We have speculated that the MERRF A to G point mutation
at the 8344 position of mt tRNALys may act as a negative
determinant that inhibits the biosynthesis of both the C5 and
2-thio modifications involved in generating m5s2U (5, 7). Be-
cause we have found that human MTU1 is a mitochondrial
specific 2-thiouridylase that participates in generating m5s2U
of mt tRNAs, it will be possible to determine whether and how
MTU1 can recognize MERRF mt tRNALys molecules once the
biosynthetic pathway leading to the 2-thio modification can be
reconstituted in vitro. If we find that the 8344 mutation is in a
critical position for MTU1 recognition, it may be that MTU1
recognizes the whole architecture of mt tRNAs, because posi-
tion 8344 in mt tRNALys is far from the wobble position. Fur-
thermore, if we could successfully design mutant MTU1 mole-
cules that efficiently recognize MERRF mt tRNALys molecules,
it may be possible to restore the 2-thio modification of MERRF
mt tRNALys by introducing the mutant MTU1 from a plasmid
vector. This could potentially lead to the development of a gene
therapy for MERRF.
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